Literature DB >> 11555694

Platelet activation by sustained exposure to low-dose plasmin.

A L Ervin1, E I Peerschke.   

Abstract

Plasmin has been reported to activate and inhibit platelet function depending on dose and exposure temperature. The present study examines the induction of fibrinogen-dependent platelet aggregation following prolonged (60 min) platelet exposure to very low doses of plasmin (0.05 CU/ml) at either 22 or 37 degrees C. Maximum aggregation [mean +/- SD, 60 +/- 19 light transmission units (LTU); n = 43] occurred following platelet exposure to plasmin at 22 degrees C, but significant platelet aggregation (28 +/- 4 LTU, n = 3) also occurred following plasmin treatment at 37 degrees C. Plasmin-induced platelet aggregates appeared microscopically larger than aggregates of adenosine diphosphate (ADP)-activated platelets, and were less reversible. Aggregated plasmin-treated platelets also expressed more procoagulant activity than platelets aggregated with ADP, as reflected by shortening of the plasma kaolin recalcification time. Aggregation of platelets exposed to very low doses of plasmin was not accompanied by dense or alpha-granule secretion, and was unaffected by ADP antagonists or aspirin. Partial inhibition of platelet aggregation, however, was achieved with metabolic inhibitors, PGE1, and inhibitors of phosphoinositide 3-kinase or protein kinase C. Although fibrinogen was required for plasmin-treated platelet aggregation, [125I]-fibrinogen binding comprised only 58 +/- 3% (n = 3) of fibrinogen binding associated with ADP aggregated platelets. This was consistent with observed decreases in reptilase-induced fibrin clot retraction. Taken together, these data suggest that sustained exposure of platelets to very low plasmin doses leads to platelet activation and thus may contribute to thrombotic complications in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555694     DOI: 10.1097/00001721-200109000-00001

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Effects of tranexamic acid on platelet function and thrombin generation (ETAPlaT): WOMAN trial sub-study.

Authors:  Kastriot Dallaku; Haleema Shakur; Ian Roberts; Phil Edwards; Danielle Beaumont; Maria Delius; Braun Siegmund; Orion Gliozheni; Ilir Tasha; Saimir Cenameri; Ulrich Mansmann
Journal:  Wellcome Open Res       Date:  2016-12-15

2.  The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes.

Authors:  Catherine P M Hayward; Minggao Liang; Subia Tasneem; Asim Soomro; John S Waye; Andrew D Paterson; Georges E Rivard; Michael D Wilson
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

3.  No effect of tranexamic acid on platelet function and thrombin generation (ETAPlaT) in postpartum haemorrhage: a randomised placebo-controlled trial.

Authors:  Kastriot Dallaku; Haleema Shakur-Still; Danielle Beaumont; Ian Roberts; Sumaya Huque; Maria Delius; Stefan Holdenrieder; Orion Gliozheni; Ulrich Mansmann
Journal:  Wellcome Open Res       Date:  2019-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.